453: Does a Difference in Molecular Diagnostic Test Results Exist between Proliferation Signal Inhibitors and Mycophenolic Acid in Cardiac Allograft Recipients?

Abstract

Mycophenolic acid (MPA) and Proliferation Signal Inhibitors (PSIs) are routinely used in conjunction with calcineurin inhibitors (CNIs) for immunosuppression in cardiac allograft recipients. PSIs bind to FK-binding protein-12, and inhibit m-TOR. MPA inhibits de novo purine synthesis in B and T lymphocytes. These immunosuppressive agents may have differential effects on gene expression. Molecular diagnostic testing (MDT) developed from the CARGO study assesses immune activation in cardiac allograft recipients on the basis of gene expression profiling.